Search results
Results from the WOW.Com Content Network
Systemic mastocytosis involves the bone marrow in the majority of cases and in some cases other internal organs, usually in addition to involving the skin. Mast cells collect in various tissues and can affect organs where mast cells do not normally inhabit such as the liver , spleen and lymph nodes , and organs which have normal populations but ...
A mast cell (also known as a mastocyte or a labrocyte [1]) is a resident cell of connective tissue that contains many granules rich in histamine and heparin.Specifically, it is a type of granulocyte derived from the myeloid stem cell that is a part of the immune and neuroimmune systems.
A mastocytoma or mast cell tumor is a type of round-cell tumor consisting of mast cells.It is found in humans and many animal species; it also can refer to an accumulation or nodule of mast cells that resembles a tumor.
In a small proportion of cases, acute mast cell leukemia may evolve from a more progressive form of systemic mastocytosis. The diagnosis of acute mast cell leukemia by the WHO criteria includes the requirement for a prevalence of 20% neoplastic mast cells in marrow and 10% in blood. [ 1 ]
Mast cell activation syndrome (MCAS) is a term referring to one of two types of mast cell activation disorder (MCAD); the other type is idiopathic MCAD. [1] MCAS is an immunological condition in which mast cells, a type of white blood cell, inappropriately and excessively release chemical mediators, such as histamine, resulting in a range of chronic symptoms, sometimes including anaphylaxis or ...
Myelophthisic anemia (also known as myelophthisis) is a severe kind of anemia found in some people with diseases that affect the bone marrow. Myelophthisis is the displacement of hemopoietic bone-marrow tissue into the peripheral blood, [51] either by fibrosis, tumors or granulomas. Neuroacanthocytosis: 29707: D054546
The more aggressive forms of disease require treatment with chemotherapy, radiotherapy, immunotherapy and—in some cases—a bone marrow transplant. The use of rituximab has been established for the treatment of B-cell–derived hematologic malignancies, including follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). [7]
This syndrome affects bone marrow cells causing treatment-resistant anemia and myelodysplastic syndromes that may lead to acute myelogenous leukemia. Examination of the bone marrow shows characteristic changes in the megakaryocytes. They are more numerous than usual, small and mononuclear. There may be accompanying erythroid hypoplasia in the ...